As part of our series focussing on medicines available in Australia, we have added a product review on beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide (BDP/FF/GB) an extrafine formulation single-inhaler triple therapy for adults with moderate-to-severe chronic obstructive pulmonary disease not adequately controlled with dual therapy. This publication outlines the pharmacological and clinical properties of BDP/FF/GB and summarises real-world evidence.
It also provides commentary and guidance from Dr Sanjay Ramakrishnan, a respiratory physician and clinician scientist at Sir Charles Gairdner Hospital and the University of Western Australia, Perth, Australia.
Please login below to download this issue (PDF)